WALTHAM, Mass.–(BUSINESS WIRE)–BostonGene, developer of the leading AI model for tumor and immune biology, announced today the acceptance of six abstracts at the ESMO Congress 2026. As a premier global platform for oncology hosted by the European Society for Medical Oncology, the ESMO Congress brings together international experts to showcase practice-changing research and clinical breakthroughs across cancer care. Demonstrating the power of biologically grounded AI for drug development and p

Subscribe to Our Newsletter

We keep your data private and share your data only with third parties that make this service possible. See our Privacy Policy for more information.